author-photo

Narayana I. Narasimhan

ARIAD Pharmaceuticals, Inc.

42

Papers

2517

Citations

Citation Trend

Filter By

Papers (42) Sort By

JournalConferenceOthers

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P6-21-07: The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, and the CDK4/6 inhibitors palbociclib or abemaciclib synergistically enhance each other's in vitro and in vivo anticancer activity

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Abstract P6-20-11: The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

2018 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans

2017 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (24)
First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (78)
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study

2017 International Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (18)
Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (20)
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (181)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号